Section Arrow
Quote
BCAX.NASDAQ
- Bicara Therapeutics Inc.
Quotes are at least 15-min delayed:2025/09/01 15:45 EDT
Regular Hours
Last
 11.94
+0.03 (+0.25%)
Day High 
12.005 
Prev. Close
11.91 
1-M High
12.3 
Volume 
189.26K 
Bid
11
Ask
12.5
Day Low
11.6 
Open
11.93 
1-M Low
9.57 
Market Cap 
649.84M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 11.63 
20-SMA 11.17 
50-SMA 10.6 
52-W High 28.09 
52-W Low 7.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.66/-2.64
Enterprise Value
649.97M
Balance Sheet
Book Value Per Share
7.98
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed：2025/09/01 15:45 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.